Ethics declarations Conflict of interest Drs Ji-Guang Wang and Yan Li reports having received consulting and lecture fees from Viatris China (Shanghai, China)
Currently, CAR-T therapy has demonstrated significant clinical efficacy, and the FDA has approved seven products for the treatment of hematological malignancies: Kymriah, a CD19-specific CAR-T product, was the first to be approved on August 31, 2017, for treating patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia (B-ALL) (38)
The compounds research relevance to joint and inflammatory pathways centers on its documented effects on inflammatory cell behavior and tissue repair mechanisms
Though the result varies from person to person depending upon their metabolic capacity, people mostly get desired result within that period
References: Jett L, Lger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP
The name is marketing shorthand, not a medical descriptor
